Vermillion to Discuss Preliminary Results for Fourth Quarter and Full Year
2012 on Wednesday, February 20, 2013, at 4:30 p.m. ET
AUSTIN, Texas, Feb. 8, 2013
AUSTIN, Texas, Feb. 8, 2013 /PRNewswire/ --Vermillion, Inc. (NASDAQ: VRML), a
molecular diagnostics company focused on gynecologic cancers and vascular
medicine, will hold a conference call on Wednesday, February 20, 2013, at 4:30
p.m. ET to discuss preliminary results for its fourth quarter and full year
2012 ended December, 31, 2012. Select preliminary unaudited results will be
issued in a press release prior to the call.
Vermillion's interim CEO Bruce A. Huebner will host the call, followed by a
question and answer period.
Date: Wednesday, February 20, 2013
Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time)
Dial-In Number: 1-800-909-4761
Conference ID#: 21648726
The conference call will be webcast live and available for replay via the
investor section of the company's website at www.vermillion.com.
Please call the conference telephone number 5-10 minutes prior to the start
time. An operator will register your name and organization. If you have any
difficulty connecting with the conference call, please contact Liolios Group
A replay of the call will be available approximately two hours after the call
through March 6, 2013.
Toll-free replay number: 1-800-633-8284
International replay number: 1-402-977-9140
Replay pin number: 21648726
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and
commercialization of novel high-value diagnostic tests that help physicians
diagnose, treat and improve outcomes for patients. Vermillion, along with its
prestigious scientific collaborators, has diagnostic programs in oncology,
vascular medicine and women's health. Additional information about Vermillion
can be found at www.vermillion.com.
Investor Relations Contact:
Liolios Group, Inc.
SOURCE Vermillion, Inc.
Press spacebar to pause and continue. Press esc to stop.